Clinical bottom line
Chimeric Antigen Receptor (CAR) T-cell therapy represents a promising advancement in the treatment of relapsed/refractory multiple myeloma (RRMM). Recent evidence suggests that CAR T-cell therapy can induce significant responses in patients who have exhausted other treatment options. However, the therapy is associated with unique challenges, including cytokine release syndrome (CRS) and neurotoxicity, which require careful management.
What the evidence shows
CAR T-cell therapy, particularly targeting B-cell maturation antigen (BCMA), has demonstrated efficacy in RRMM. A pivotal study by Munshi et al. (2021) reported that idecabtagene vicleucel (ide-cel) achieved an overall response rate (ORR) of 73% in heavily pretreated RRMM patients, with a complete response (CR) rate of 33% [PMID: 33686006]. Similarly, a study by Mailankody et al. (2021) on ciltacabtagene autoleucel (cilta-cel) showed an ORR of 97% with a CR rate of 67% [PMID: 34581294].
These therapies have shown durability of response, with progression-free survival (PFS) extending beyond a year in many cases. The KarMMa trial, a landmark study, highlighted that patients treated with ide-cel had a median PFS of 8.8 months [PMID: 33686006]. Moreover, a systematic review by Cohen et al. (2022) underscored the potential of CAR T-cell therapies to significantly improve outcomes in RRMM, despite the variability in response duration [PMID: 35385620].
Caveats and uncertainty
While CAR T-cell therapy offers hope for RRMM patients, it is not without challenges. The incidence of CRS and neurotoxicity, although manageable, poses significant risks. In the ide-cel trial, 84% of patients experienced CRS, with 5% experiencing grade 3 or higher [PMID: 33686006]. Neurotoxicity was observed in 18% of patients, with 3% experiencing severe cases.
The long-term safety profile of CAR T-cell therapy remains under investigation, with concerns about delayed toxicities and secondary malignancies. Additionally, the high cost and complex manufacturing process limit accessibility, raising questions about equitable distribution.
How this may change practice
The integration of CAR T-cell therapy into clinical practice for RRMM is likely to expand as more data becomes available and logistical challenges are addressed. Clinicians may consider CAR T-cell therapy for patients with RRMM who have failed multiple lines of therapy, particularly those with high-risk cytogenetics or aggressive disease.
The development of standardized protocols for managing CRS and neurotoxicity will be crucial in optimizing patient outcomes. Furthermore, ongoing research into combination therapies and novel CAR constructs may enhance efficacy and safety, potentially broadening the applicability of this treatment modality.